[144] Constellation Brands, Inc. SEC Filing

Rhea-AI Filing Summary

On 07/17/2025 Kestra Medical Technologies (KMTS) filed a Form 4 for CFO Vaseem Mahboob. The executive acquired 22,059 restricted stock units (RSUs) at no cost (code A). Following the grant, his direct ownership rose to 36,897 common shares.

The RSUs will vest in three equal tranches: 7,353 shares on 17 Jul 2026 and 2027, and 7,354 shares on 17 Jul 2028, subject to continued service. Mahboob also holds 159,000 stock options; 79,500 options vest on 06 Mar 2026, with the remaining 79,500 vesting monthly over the subsequent year. No sale or cash purchase occurred; the transaction represents routine equity compensation aimed at retention and alignment of incentives.

No other insider activity or material company information is disclosed in this filing.

Insights

Financial Analyst

TL;DR: Routine RSU grant increases CFO ownership; negligible immediate market impact.

The Form 4 reflects a standard compensation award rather than an open-market buy. The 22,059 RSUs raise Mahboob’s stake by roughly 149%, signalling commitment but not indicating an independent valuation view. Vesting through 2028 supports long-term retention. The 159,000 options, already disclosed in prior filings, carry the same vesting schedule, so dilution effects were anticipated. With no cash outlay or new financing, the filing is neutral for valuation and liquidity. Investors may see modestly positive governance optics, but trading impact should be minimal.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	821	138749.00	176293406	07/21/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2024	Restricted Stock	Issuer			188	05/01/2024	Not Applicable
Common	05/01/2025	Restricted Stock	Issuer			264	05/01/2025	Not Applicable
Common	05/01/2023	Restricted Stock	Issuer			186	05/01/2023	Not Applicable
Common	05/01/2022	Restricted Stock	Issuer			183	05/01/2022	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Kestra Medical Technologies (KMTS) shares did the CFO acquire?

22,059 restricted stock units were granted on 17 Jul 2025.

What is the vesting schedule for the newly granted RSUs?

The RSUs vest 7,353 shares on 17 Jul 2026 and 2027, and 7,354 shares on 17 Jul 2028.

How many KMTS shares does the CFO now beneficially own?

After the grant, he owns 36,897 common shares directly.

What derivative securities does the CFO hold?

He holds 159,000 stock options; 79,500 vest on 06 Mar 2026, the rest monthly over the following year.

Was any cash paid for the RSUs?

No. The transaction code "A" indicates a no-cost award under the company’s compensation plan.